Literature DB >> 17984670

Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study.

Anne Sofie Astrup1, Flemming S Nielsen, Peter Rossing, Samir Ali, Jens Kastrup, Ulla Meng Smidt, Hans-Henrik Parving.   

Abstract

OBJECTIVE: To evaluate the prognostic significance of cardiovascular risk factors including 24-h ambulatory blood pressure level and rhythm for all-cause mortality in type 2 diabetic patients.
METHODS: In a prospective observational study, 104 patients with type 2 diabetes were followed: 51 patients with diabetic nephropathy and 53 patients with persistent normoalbuminuria. At baseline, 24-h ambulatory blood pressure, left ventricular hypertrophy, glomerular filtration rate and cardiac autonomic neuropathy were measured. Blood samples were taken and patients answered a World Health Organization questionnaire. Dipping was calculated as the average nocturnal reduction in systolic and diastolic blood pressure.
RESULTS: Mean follow-up was 9.2 years (range 0.5-12.9). During follow-up, 54 of 104 patients died. Sixteen patients (15%) had higher blood pressure at night than during the day (reversed pattern); 14 of these patients died (88%), compared to 40 of 88 patients (45%) with reduced dipping or normal dipping; log rank P = 0.001. In a Cox regression analysis, predictors of all-cause mortality were: age, male sex, presence of left ventricular hypertrophy, glycated haemoglobin A1c (HbA1c), daytime systolic blood pressure, cardiac autonomic neuropathy, glomerular filtration rate and dipping (1% increase; hazard ratio 0.97, 95% confidence interval 0.94-0.998, P = 0.033).
CONCLUSION: Type 2 diabetes patients with non-dipping of night blood pressure were at higher risk of death as compared to dippers, independent of known cardiovascular risk factors. Since non-dipping has a high prevalence in patients with diabetic nephropathy, 24-h ambulatory blood pressure should be used to assess a full risk profile and blood pressure-lowering therapy in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984670     DOI: 10.1097/HJH.0b013e3282f06428

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  27 in total

Review 1.  Improvements in heart rate variability with exercise therapy.

Authors:  Faye S Routledge; Tavis S Campbell; Judith A McFetridge-Durdle; Simon L Bacon
Journal:  Can J Cardiol       Date:  2010 Jun-Jul       Impact factor: 5.223

2.  Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes.

Authors:  Kouichi Tamura; Hiromichi Wakui; Kengo Azushima; Kazushi Uneda; Satoshi Umemura
Journal:  Hypertens Res       Date:  2016-01-28       Impact factor: 3.872

3.  Ambulatory pulse pressure, decreased nocturnal blood pressure reduction and progression of nephropathy in type 2 diabetic patients.

Authors:  S T Knudsen; E Laugesen; K W Hansen; T Bek; C E Mogensen; P L Poulsen
Journal:  Diabetologia       Date:  2009-01-29       Impact factor: 10.122

Review 4.  Chronotherapy improves blood pressure control and reduces vascular risk in CKD.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; Artemio Mojón; José R Fernández; Juan J Crespo; Ana Moyá; María T Ríos; Francesco Portaluppi
Journal:  Nat Rev Nephrol       Date:  2013-04-23       Impact factor: 28.314

5.  Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Diabetologia       Date:  2015-09-23       Impact factor: 10.122

6.  Sleep-time BP: prognostic marker of type 2 diabetes and therapeutic target for prevention.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Diabetologia       Date:  2015-09-23       Impact factor: 10.122

Review 7.  Around-the-clock ambulatory blood pressure monitoring is required to properly diagnose resistant hypertension and assess associated vascular risk.

Authors:  Ramón C Hermida; Diana E Ayala; María T Ríos; José R Fernández; Artemio Mojón; Michael H Smolensky
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

8.  The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.

Authors:  Mai Yanagi; Kouichi Tamura; Tetsuya Fujikawa; Hiromichi Wakui; Tomohiko Kanaoka; Masato Ohsawa; Kengo Azushima; Akinobu Maeda; Hiroyuki Kobori; Satoshi Umemura
Journal:  Hypertens Res       Date:  2012-11-15       Impact factor: 3.872

9.  Racial differences in the impact of social support on nocturnal blood pressure.

Authors:  Denise C Cooper; Michael G Ziegler; Richard A Nelesen; Joel E Dimsdale
Journal:  Psychosom Med       Date:  2009-03-25       Impact factor: 4.312

10.  Ambulatory blood pressure monitoring and all-cause mortality in elderly people with diabetes mellitus.

Authors:  Walter Palmas; Thomas G Pickering; Jeanne Teresi; Joseph E Schwartz; Andrew Moran; Ruth S Weinstock; Steven Shea
Journal:  Hypertension       Date:  2009-01-05       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.